FDA Approves Kisunla™ A New Drug for Alzheimer’s Treatment
Another important step forward in the fight against Alzheimer’s disease was reached last Tuesday, with the Food and Drug Administration (FDA) approval of Kisunla™ (generic name donanemab), developed by Eli Lilly. Kisunla™ is the third FDA approved disease modifying treatment, [View More]